Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT03425474
- Locations
- 🇨🇳
Clinical trial Ethnics Committee of Peking Union Medical College Hospital, Beijing, Beijing, China
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT03417895
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- Drug: HTI-1066 dose level 2Drug: HTI-1066 dose level 3Drug: HTI-1066 dose level 4Drug: HTI-1066 dose level 1
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03398720
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Sarah Cannon - Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT03363555
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Drug-drug Interaction Between Simvastatin and SHR3824
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03329118
Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects
- Conditions
- Sedation
- Interventions
- Drug: Intranasal PlaceboDrug: Intravenous Placebo
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03293277
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT03254966
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study To Test The Effect Of Apatinib On P450 Enzymes
- Conditions
- Cytochrome P450 Interaction
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03245307
- Locations
- 🇨🇳
Chinese Medical University First Hospital, Shenyang, Liaoning, China
Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Drug: matching placebo
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT03222843
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan, Hubei, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT03185793
- Locations
- 🇨🇳
Jiangsu Hengrui Medicine Co., Ltd., Shanghai, Shanghai, China